NASDAQ
Sarepta Therapeutics, Inc. (SRPT)
♥ 569 Thanks from members
Sarepta Therapeutics (SRPT) presents a mixed financial outlook, beating Q2 2026 earnings and sales estimates despite a 34% year-over-year total revenue decline. While the new CEO transition under Michael Severino brings leadership clarity, the company faces mounting commercial headwinds, including weaker Elevidys sales, Roche Phase 3 study efficacy risks, and rising competition in the Duchenne muscular dystrophy space.